Continuing versus stopping prestroke antihypertensive therapy in acute intracerebral hemorrhage: a subgroup analysis of the efficacy of nitric oxide in stroke trial by Krishnan, Kailash et al.
Continuing versus Stopping Prestroke Antihypertensive
Therapy in Acute Intracerebral Hemorrhage: A Subgroup
Analysis of the Efficacy of Nitric Oxide in Stroke Trial
Kailash Krishnan, MRCP,* Polly Scutt, MSc,* Lisa Woodhouse, MSc,*
Alessandro Adami, MD,† Jennifer L. Becker, MD, FRCR,‡ Lesley A. Cala, MD, FRCR,§
Ana M. Casado, MD,‖ Christopher Chen, MRCP, FAMS,¶
Robert A. Dineen, PhD, FRCR,# John Gommans, FRACP,**
Panos Koumellis, MRCP, FRCR,†† Hanna Christensen, MD, PhD,‡‡
Ronan Collins, MD, FRCPI,§§ Anna Czlonkowska, MD, PhD,‖‖
Kennedy R. Lees, MD, FRCP,¶¶ George Ntaios, MD, PhD,## Serefnur Ozturk, MD,***
Stephen J. Phillips, MBBS, FRCPC,††† Nikola Sprigg, DM, MRCP,*
Szabolcs Szatmari, MD,‡‡‡ Joanna M. Wardlaw, FRCR, FMedSci,‖
Philip M. Bath, DSc, FRCP* for the ENOS Investigators
Background and purpose: More than 50% of patients with acute intracerebral hem-
orrhage (ICH) are taking antihypertensive drugs before ictus. Although
antihypertensive therapy should be given long term for secondary prevention,
whether to continue or stop such treatment during the acute phase of ICH remains
unclear, a question that was addressed in the Efficacy of Nitric Oxide in Stroke
(ENOS) trial. Methods: ENOS was an international multicenter, prospective,
randomized, blinded endpoint trial. Among 629 patients with ICH and systolic
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blood pressure between 140 and 220 mmHg, 246 patients who were taking anti-
hypertensive drugs were assigned to continue (n = 119) or to stop (n = 127) taking
drugs temporarily for 7 days. The primary outcome was the modified Rankin Score
at 90 days. Secondary outcomes included death, length of stay in hospital, dis-
charge destination, activities of daily living, mood, cognition, and quality of life.
Results: Blood pressure level (baseline 171/92 mmHg) fell in both groups but was
significantly lower at 7 days in those patients assigned to continue antihyperten-
sive drugs (difference 9.4/3.5 mmHg, P < .01). At 90 days, the primary outcome
did not differ between the groups; the adjusted common odds ratio (OR) for worse
outcome with continue versus stop drugs was .92 (95% confidence interval, .45-
1.89; P = .83). There was no difference between the treatment groups for any secondary
outcome measure, or rates of death or serious adverse events. Conclusions: Among
patients with acute ICH, immediate continuation of antihypertensive drugs during
the first week did not reduce death or major disability in comparison to stop-
ping treatment temporarily. Key Words: Antihypertensive therapy—blood
pressure—glyceryl trinitrate—intracerebral hemorrhage—cerebrovascular
disorders—randomized controlled trial.
© 2016 The Authors. Published by Elsevier Inc. on behalf of National Stroke
Association. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Introduction
High blood pressure (BP) is present in 75% of pa-
tients with acute intracerebral hemorrhage (ICH) and is
substantially higher than premorbid levels.1-3 Raised BP
occurs secondary to multiple factors, including neuro-
endocrine activation and increasing intracranial pressure,
and is associated with a poor outcome.4-7 More than 50%
of patients with acute ICH are taking antihypertensive
drugs before their stroke and hospital admission.
Although lowering BP long term after stroke is key for
secondary prevention,8 it remains unclear whether prestroke
antihypertensive drugs should be continued or stopped
temporarily during the acute phase.9 Arguments both for
and against each strategy can be postulated and guide-
lines lack firm recommendations related to this subject.10,11
Continuing prior antihypertensive drugs after ICH might
limit hematoma expansion, reduce the development of ce-
rebral edema and early recurrence, and improve long-
term outcome.8,12 And yet, continuing treatment may lead
to the development of hypotension, thereby compromis-
ing regional cerebral perfusion because of dysfunctional
cerebral autoregulation.13 Further, continuing treatment in-
volves administering tablets at a time when many patients
have dysphagia and limited enteral access, a risk for as-
piration pneumonia. Stopping treatment may result in
secondary prevention being forgotten, thereby raising the
risk of recurrent events and worsening outcomes long term.
Two trials have examined the question of whether
prestroke BP drugs should be continued or stopped tem-
porarily during the acute phase of stroke. The Continue
or Stop Post-Stroke Antihypertensives Collaborative Study
(COSSACS) found no difference in functional outcome,
death, or serious adverse events, although it had low sta-
tistical power with only 763 participants recruited from
a planned analysis of 2900 patients.14 No differential effect
in patients with ICH versus ischemic stroke was re-
ported. The Efficacy of Nitric Oxide in Stroke (ENOS) trial
assessed the effects of glyceryl trinitrate (GTN) versus
no GTN in 4011 participants with acute stroke; patients
who were taking prestroke antihypertensive medica-
tions were also randomized to continue or stop these for
7 days in a partial factorial design.15 Although ENOS was
neutral for both interventions,16 a subgroup of patients
randomized to continue treatment within 12 hours had
a worse functional outcome (unpublished data), an effect
also seen in a meta-analysis of individual patient data
from COSSACS and ENOS combined (Woodhouse et al,
unpublished). Here, we report the results of a preplanned
subgroup analysis of patients with ICH enrolled in ENOS
and who were randomized to continue versus stop
prestroke antihypertensive therapy,17 including those ran-
domized within 12 hours of stroke onset.
Methods
ENOS Trial
Details of the ENOS study protocol, statistical analy-
sis plan, patient characteristics at baseline, and main results
have been published (ISRCTN99414122).15-18 In brief, ENOS
was a prospective, international, multicenter, random-
ized, blinded endpoint trial recruiting patients within 48
hours of ischemic stroke or ICH. Patients aged over 18
years with systolic blood pressure (SBP) level of 140-
220 mmHg and who did not have a definite need for,
or contraindication to, BP-lowering treatment were eli-
gible. Randomization was performed centrally by computer
to GTN (5 mg each morning) or no GTN, and, where rel-
evant, to continue or stop taking prior antihypertensive
1018 K. KRISHNAN ET AL.
drugs temporarily for 7 days. Randomization included
stratification by stroke type (ICH versus ischemic stroke
or stroke of unknown type) and minimization on key prog-
nostic variables. GTN and no GTN were given with the
patient masked to treatment; prestroke antihypertensive
drugs were given open label.
In participants assigned to continue antihypertensive
drugs, medication was administered orally, and those with
dysphagia received treatment through a nasogastric feeding
tube. If oral or tube feeding was not possible, treatment
was withheld until feasible. Open-label antihyperten-
sive drugs could be administered during the treatment
period according to clinical need. During treatment, BP
was measured once daily using a validated automatic clin-
ical monitor (Omron HEM-705 CP or HEM-757; OMRON
Healthcare Company, Kyoto, Japan)19 with a cuff of suit-
able size. After day 7, antihypertensive therapy that had
been stopped was restarted according to clinical need.
The trial protocol was approved by the national ethics
committee in each participating country and all pa-
tients or surrogates gave informed consent. In this subgroup
analysis, we included all patients with ICH recruited into
the continue versus stop prestroke antihypertensive drugs
part of ENOS.
Outcomes
The primary outcome was the modified Rankin Scale
(mRS scores: 0 = no residual disability, 5 = bedbound and
requiring 24-hour care, 6 = death20) assessed at day 90.
Key secondary outcomes were activities of daily living
(Barthel Index scores: 0 = severe disability to 100 = no
disability21), cognition (modified telephone Mini-Mental
State Examination [t-MMSE] scores: 0 = severe demen-
tia to 18 = normal22; Telephone Interview for Cognition
Scale [TICS-M] scores: 0 = severe dementia to 37 = normal23;
verbal fluency as animal naming scores: 0 = none to in-
finity), health-related quality of life (European Quality of
Life-5 Dimensions [EQ-5D],24 from which health utility
status [HUS] was calculated, scores: −.594 = very poor,
0 = death to 1.0 = perfect; European Quality of Life-
Visual Analogue Scale [EQ-VAS] scores: 0 = very poor to
100 = excellent), and mood (short Zung depression Score
[ZDS] scores: 0 = normal to 100 = severe depression25). The
final follow-up was by telephone interview conducted by
trained investigators blinded to treatment assignment at
the trial-coordinating center. A postal questionnaire cov-
ering the outcome measures was sent if the patient could
not be contacted. Safety outcomes included death, early
neurological deterioration (defined as a decrease of at least
5 points on the Scandinavian Stroke Scale (SSS) from base-
line to day 7 and/or a decrease in consciousness of more
than 2 points on the SSS consciousness domain), recur-
rent stroke by day 7, hypotension (requiring intervention
such as leg elevation or administration of fluids), hyper-
tension (requiring treatment to lower BP), and serious
adverse events. Serious adverse events whether related
to treatment (definite, uncertain, no causality, unknown)
and the systems affected by the adverse event were re-
corded by the local investigators.
Imaging
For each patient, scan images were adjudicated cen-
trally by expert neuroradiologists and trained physicians
masked to clinical data and treatment allocation. Col-
lected information included the presence of location of
hemorrhage in the brain, an estimate of size and the pres-
ence of mass effect, atrophy, white matter disease, and
old infarct or hemorrhage using validated scoring tools.26,27
Hematoma parameters including volume, shape, density,
shape index, density index, and presence of blood in the
ventricles were also measured.28-34
Analyses
As for the mRS and HUS, which have a separate cat-
egory for death, we assigned an extreme score for death
when analyzing each of the other outcome scale. The values
used were −5: Barthel Index score; −1: EQ-VAS, SSS,
t-MMSE, TICS-M, and verbal fluency; 0: EQ-5D/HUS; and
102.5: ZDS.16,17 Comparisons were performed with binary
logistic regression (dichotomous data), Cox regression
(death), ordinal logistic regression (ordered categorical
data),35 or multiple linear regression (continuous data).
Analyses were adjusted for prognostic covariates: age, sex,
premorbid mRS score, history of previous stroke, history
of diabetes, severity (SSS), stroke syndrome (total ante-
rior circulation versus other), SBP, feeding status, time
to randomization, and treatment assignment (GTN versus
no GTN). Heterogeneity of the treatment effect was as-
sessed by including an interaction term in the adjusted
statistical model for each of the following predefined sub-
groups: age, time to randomization, presence of ipsilateral
carotid stenosis, number of prestroke antihypertensive drugs,
feeding status, stroke severity, BP level at the time of ran-
domization, feeding status, and treatment with GTN or
no GTN. Analysis was performed using SPSS software
version 22 (SPSS Statistics, Chicago, IL) on an Apple iMac
computer (Apple Inc, Cupertino, California, USA). P values
less than .05 were considered as statistically significant.
Results
Recruitment into ENOS ran between July 2001 and
October 2014. During this period, 629 patients with ICH
were recruited into the trial, with 246 patients random-
ized to continue (n = 119) or stop (n = 127) antihypertensive
drugs (Table 1). Thirty-nine patients were randomized
within 12 hours (continue 18, stop 21). The treatment
groups were well matched at baseline, with a mean age
of 69 years, were male 59%, and had a mean BP level
of 171/92 mmHg and a SSS severity score of 29.6
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Table 1. Baseline clinical characteristics of 246 patients with intracerebral hemorrhage and those randomized within 12 hours
Characteristics All Continue Stop 12 h or less Continue Stop 2P
Number of patients (N) 246 119 127 39 18 21
Country, United Kingdom
(%)
138 (56.1) 68 (57.1) 70 (55.1) 20 (51.3) 10 (55.6) 10 (47.6) .52
Age (years) 69.2 (11.5) 68.8 (11.3) 69.6 (11.6) 68.3 (13.0) 67.1 (13.7) 69.3 (12.6) .58
Sex, male (%) 144 (58.5) 70 (58.8) 74 (58.3) 25 (64.1) 13 (72.2) 12 (57.1) .44
Smoking, current (%) 37 (15.5) 20 (17.4) 17 (13.8) 4 (10.8) 2 (11.8) 2 (10.0) .19
Premorbid mRS
score > 0 (%)
81 (32.9) 43 (36.1) 38 (29.9) 9 (23.1) 5 (27.8) 4 (19.0) .23
Previous stroke (%) 45 (18.3) 20 (16.8) 25 (19.7) 3 (7.7) 0 3 (14.3) .06
Prior antihypertensive (%) 241 (98.0) 116 (97.5) 125 (98.4) 39 (100.0) 18 (100.0) 21 (100.0) .33
Number of BP drugs (%)
0 3 (1.2) 1 (.8) 2 (1.6) — — — —
1 107 (43.5) 55 (46.2) 52 (40.9) 20 (51.3) 13 (72.2) 7 (33.3) .22
2 58 (23.6) 28 (23.5) 30 (23.6) 9 (23.1) 3 (16.7) 6 (28.6) .47
3 25 (10.2) 8 (6.7) 17 (13.4) 5 (12.8) 1 (5.6) 4 (19.0) 1.00
4 11 (4.5) 4 (3.4) 7 (5.5) 2 (5.1) 1 (5.6) 1 (4.5) 1.00
5 1 (.4) 1 (.8) 0 — — — —
Treated BP agent (%)
ACE-I 106 (43.1) 51 (42.9) 55 (43.3) 17 (43.6) 6 (33.3) 11 (52.4) .29
ARA 49 (19.9) 24 (20.2) 25 (19.7) 5 (12.8) 1 (5.6) 4 (19.0) .35
Beta-receptor
antagonist
70 (28.5) 26 (21.8) 44 (34.6) 10 (25.6) 3 (16.7) 7 (33.3) .73
Calcium channel
blocker
95 (38.6) 43 (36.1) 52 (40.9) 18 (46.2) 5 (27.8) 13 (61.9) .12
Centrally acting agent 8 (3.3) 4 (3.4) 4 (3.1) 2 (5.1) 1 (5.6) 1 (4.8) 1.00
Diuretic 63 (25.6) 34 (28.6) 29 (22.8) 11 (28.2) 7 (38.9) 4 (19.0) .53
Alpha-receptor
antagonist
13 (5.3) 8 (6.7) 5 (3.9) 3 (7.7) 2 (11.1) 1 (4.8) 1.00
Other 3 (1.2) 1 (.8) 2 (1.6) 0 — — —
Previous high BP (%) 238 (96.7) 115 (96.6) 123 (96.9) 39 (100.0) 18 (100.0) 21 (100.0) .21
Diabetes mellitus (%) 49 (19.9) 22 (18.5) 27 (21.3) 10 (25.6) 4 (22.2) 6 (28.6) .33
Ischemic heart
disease (%)
39 (15.9) 18 (15.1) 21 (16.5) 4 (10.3) 1 (5.6) 3 (14.3) .58
Atrial fibrillation (%) 28 (11.4) 13 (10.9) 15 (11.8) 5 (12.8) 1 (5.6) 4 (19.0) .75
TACS (%) 89 (36.2) 44 (37.0) 45 (35.4) 10 (25.6) 8 (44.4) 2 (9.5) .15
SSS score (/58) 29.6 (12.6) 28.5 (12.3) 30.6 (12.9) 31.3 (11.4) 27.4 (12.4) 34.6 (9.4) .37
NIHSS score (/42),
calculated36
13.0 (5.4) 13.4 (5.3) 12.5 (5.5) 12.2 (4.9) 13.9 (5.4) 10.8 (5.4) .37
Glasgow Coma Scale
score (/15)
15 (1) 15 (1) 15 (1) 15 (1) 15 (1) 15 (0) .13
SBP (mmHg) 170.8 (18.4) 169.5 (16.9) 172.1 (19.7) 175.8 (17.9) 175.0 (16.6) 176.4 (19.3) .07
DBP (mmHg) 92.3 (13.4) 93.3 (14.0) 91.4 (12.8) 96.5 (11.7) 95.6 (14.1) 97.3 (9.5) .031
Heart rate (bpm) 77.4 (15.8) 77.9 (15.9) 77.0 (15.9) 79.2 (17.9) 80.3 (15.1) 78.2 (20.3) .22
Feeding status
Normal diet 77 (31.3) 43 (36.1) 34 (26.8) 15 (38.5) 6 (33.3) 9 (42.9) .28
Soft diet 58 (23.6) 22 (18.5) 36 (28.3) 10 (25.6) 7 (38.9) 3 (14.3) .09
Nasogastric tube feeding 15 (6.1) 7 (5.9) 8 (6.3) 2 (5.1) 1 (5.6) 1 (4.8) 1.00
Percutaneous feeding tube 0 — — — — — —
IV/SC fluids 45 (18.3) 20 (16.8) 25 (19.7) 4 (10.3) 2 (11.1) 2 (9.5) 1.00
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARA, angiotensin receptor antagonist; BP, blood pressure; bpm, beats per
minute; DBP, diastolic blood pressure; IV, intravenous; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP,
systolic blood pressure; SC, subcutaneous; SSS, Scandinavian Stroke Scale; TACS, total anterior circulation syndrome.
Data are number (%), mean (standard deviation), or median (interquartile range). Comparison of patients randomized within 12 hours versus
those later by the Fischer exact test, the Mann–Whitney U-test, or t-test.
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(National Institutes of Health Stroke Scale score of ~13.0
with mean ICH volume of 12.0 cm3). Most hematomas
(89%) were located primarily in the deeper brain regions
and many patients had leukoaraiosis (70%) and/or ev-
idence of a previous stroke (51%) (Table 2); 72% of
neuroimaging was performed within 12 hours of stroke
onset.
BP
The mean BP level was 171/92 mmHg at baseline and
declined in both groups over the 7 days of randomized
treatment; by day 7, the BP level was lower by 9/4 mmHg
in the group randomized to continue treatment (Fig 1).
The baseline BP level was 176/97 mmHg in patients ran-
domized at 12 hours and was lower by 28/16 mmHg at
day 7 in those continuing treatment (Fig S1).
Clinical Outcomes
There was no difference in mRS score between the treat-
ment groups at day 90, common odds ratio for worse
outcome in the continue group .92 (95% confidence in-
terval, .45-1.89; P = .83) (Fig 2). A test of “goodness of
fit” showed no evidence that the assumption of propor-
tional odds had been violated (P = .07). There were no
significant interactions between the effect of random-
ized treatment on mRS score in preselected subgroups
Table 2. Baseline neuroimaging characteristics of 246 patients with ICH and those randomized within 12 hours
Neuroimaging parameters All Continue Stop 12 h or less Continue Stop 2P
Participants with a scan available 234 (95.1) 115 (96.6) 119 (93.7) 35 (89.7) 17 (94.4) 18 (85.7)
Time, onset to neuroimaging (%)
Less than 12 h 169 (72.2) 84 (73.0) 85 (71.4) 33 (94.3) 17 (100.0) 16 (88.9) .89
12-24 h 38 (16.2) 19 (16.5) 19 (16.0) 1 (2.9) — 1 (5.6) —
More than 24 h 27 (11.5) 12 (10.4) 15 (12.6) 1 (2.9) — 1 (5.6) —
Location of hematoma (%)
Lobar* 18 (7.7) 6 (5.2) 12 (10.1) 3 (8.6) 2 (11.8) 1 (5.6) .41
Deep† 207 (88.5) 107 (93.0) 100 (84.0) 32 (91.4) 15 (88.2) 17 (94.4) .10
Posterior‡ 9 (3.8) 2 (1.7) 7 (5.9) — — — .28
ICH volume, ABC/2 (cm3)34 12.1 (14.0) 11.5 (13.6) 12.8 (14.5) 13.1 (17.0) 21.1 (20.5) 5.2 (6.3) .67
IVH volume (cm3) 3.1 (4.6) 3.1 (4.5) 3.0 (4.8) 3.9 (3.4) 5.1 (3.5) 1.8 (2.3) .61
Longest diameter (cm) 3.2 (1.4) 3.2 (1.3) 3.3 (1.5) 3.3 (1.5) 3.8 (1.6) 2.8 (1.2) .76
Visual ICH size category (cm)26
Less than 3 113 (49.1) 53 (46.9) 60 (51.3) 17 (48.6) 5 (29.4) 12 (66.7) .25
3-5 80 (34.8) 42 (37.2) 38 (32.5) 10 (28.6) 6 (35.3) 4 (22.2)
5-8 35 (1.2) 17 (15.0) 18 (15.4) 8 (22.9) 6 (35.3) 2 (11.1)
More than 8 2 (.9) 1 (.9) 1 (.9) — — —
Shape (/5)29 3.3 (1.3) 3.4 (1.5) 3.2 (1.4) 3.4 (1.5) 4.0 (1.4) 2.8 (1.3) .69
Index31 1.7 (3.1) 1.8 (4.0) 1.6 (1.7) 1.7 (1.3) 2.2 (1.4) 1.3 (1.1) .34
Density (/5)29 2.7 (1.4) 2.6 (1.3) 2.8 (1.4) 2.7 (1.4) 2.8 (1.4) 2.5 (1.4) .84
Index30 .2 (.1) .2 (.1) .2 (.1) .2 (.1) .2 (.1) .2 (.1) .34
Graeb score32 3.4 (2.2) 3.3 (2.1) 3.4 (2.3) 4.9 (2.1) 6.2 (.8) 2.7 (1.5) .033
Modified33 5.0 (4.4) 4.9 (3.5) 5.2 (4.8) 8.0 (4.4) 10.4 (3.5) 4.0 (2.0) .034
Leukoaraiosis (%) 171 (73.1) 82 (71.3) 89 (78.8) 21 (60.0) 10 (58.8) 11 (61.1) 1.00
Mass effect (%)
No swelling to mild swelling (%) 98 (41.9) 47 (40.9) 51 (42.9) 17 (48.6) 5 (29.4) 12 (66.7) .55
Moderate to severe swelling (%) 33 (14.1) 18 (15.7) 15 (12.6) 18 (51.4) 12 (70.6) 6 (33.3) .14
Previous stroke lesion (%) 126 (53.8) 60 (52.2) 66 (55.5) 20 (57.1) 10 (58.8) 10 (55.6) .06
Brain tissue reduction (%) 153 (65.4) 77 (67.0) 76 (63.9) 22 (62.9) 12 (70.6) 10 (55.6) .42
Cortical atrophy (%) 119 (50.9) 58 (50.4) 61 (51.3) 15 (42.9) 6 (35.3) 9 (50.0) .70
Central atrophy (%) 146 (62.4) 72 (62.6) 74 (62.2) 22 (62.9) 12 (70.6) 10 (61.1) .65
Abbreviations: ACA, anterior cerebral artery; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; MCA, middle cerebral
artery; PCA, posterior cerebral artery.
Data are number (%) or mean (standard deviation). Comparison of patients randomized within 12 hours with those randomized later by
the Fisher exact test, the Mann–Whitney U-test, or t-test.
Shape index = hematoma perimeter/4∏ × surface area.
Density index = standard deviation/mean of Hounsfield units.
*Lobar: ICH centered on border-zone regions, ACA, PCA territory, and MCA territory, excluding striatocapsular regions.
†Deep: ICH centered on lacunar, MCA territory including striatocapsular regions.
‡Posterior: ICH centered on the cerebellum and/or the brain stem.
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(Fig 3). Additionally, there was no difference in mRS score
in patients randomized within 12 hours to continue versus
to stop taking prestroke BP drugs (Fig S2). The rates of
clinical hypotension and hypertension were similar between
the 2 groups (Table 3). There were no significant differ-
ences between the 2 groups at day 90 in any of the
secondary clinical outcomes (Table 3) or death (Fig S3),
or serious adverse rates (Table S1).
Discussion
In this preplanned subgroup analysis of patients in ENOS
with acute ICH, there was no difference in the primary
outcome of function between patients randomized to 7
days of continuing versus stopping prestroke antihyper-
tensive therapy17; this finding was consistent across all
prespecified subgroups of patients. Similarly, there were
no differences in safety outcomes or secondary outcome
measures at day 90.
The overall neutral results seen for the continue versus
stop comparison in ENOS (including both ischemic stroke
and ICH)16 are similar to those seen in the smaller
COSSACS trial.14 COSSACS recruited only 38 patients with
ICH and has not reported these results separately; hence,
this subgroup cannot be compared with the present
substudy. Nevertheless, the 2 trials differed in several key
Figure 1. Blood pressure levels in patients with
intracerebral hemorrhage who were randomized
to continue or stop prestroke antihypertensive drugs.
Day 0 is at randomization; day 1 is 2 hours post
randomization. Comparisons by independent t-test
at each time point (with Bonferroni correction)
and repeated analysis of variance: P value less
than .01/.01. Both SBP and DBP had signifi-
cantly diverged by day 4 (2P = .010/2P < .026).
Abbreviations: DBP, diastolic blood pressure; MD,
mean difference in SBP and DBP for the contin-
ue versus stop groups; SBP, systolic blood pressure.
Figure 2. Distribution of modified Rankin scores at day 90 in patients randomized to continue versus stop prestroke antihypertensive drugs. Comparison
by ordinal logistic regression with adjustment: common odds ratio .96 (95% CI, .60-1.51, P = .84). Abbreviation: CI, confidence interval.
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Figure 3. Subgroup analysis on the effects of functional outcome
at day 90: continue versus stop. 2P is test for interaction. Ab-
breviations: ACE-I, angiotensin-converting enzyme inhibitor;
GTN, glyceryl trinitrate; LACS, lacunar syndrome; PACS, partial
anterior circulation syndrome; POCS, posterior circulation syn-
drome; RAAS, renin–angiotensin–aldosterone system; TACS,
total anterior circulation syndrome.
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Table 3. Primary and secondary outcomes at days 7 and 90: continue versus stop prestroke antihypertensive drugs
Outcome N All Continue Stop
Unadjusted
OR/MD (95% CI) 2P
Adjusted
OR/MD (95% CI) 2P
Day 7 (or discharge) 246 119 127
Death (%) 246 6 (2.4) 2 (1.7) 4 (3.2) .53 (.09-2.92) .46 .47 (.07-3.01) .58
SSS (/58) 244 33.2 (16.1) 33.1 (16.3) 33.3 (15.9) −.3 (−4.3-3.8) .90 −.8 (−4.0-2.5) .64
Recurrent stroke (%) 245 6 (2.5) 3 (2.5) 3 (2.4) 1.06 (.21-5.36) .37 1.01 (.18-5.92) .99
SBP (mmHg) 210 155.4 (26.0) 150.6 (26.4) 160 (24.9) −6.2 (−12.2 to −.2) .043 −7.5 (−14.7 to −.3) .037
Hypotension (%) 246 3 (1.2) 2 (1.7) 1 (.8) 2.15 (.19-24.07) .53 .09 (.00-6.06) .26
Hypertension (%) 246 36 (14.6) 15 (12.6) 21 (16.5) .73 (.36-1.49) .39 .77 (.57-2.92) .54
Hospital events 244 118 126
Died in hospital (%) 244 28 (11.5) 14 (11.9) 14 (11.1) 1.08 (.49-2.37) .86 1.03 (.35-2.38) .85
Hospital stay (days) 244 11 [7,33] 12 [7,33] 11 [7,27] −1.67 (−8.38-5.03) .62 −.68 (−7.09-5.72) .83
Death or institution (%) 244 105 (43.0) 51 (43.2) 54 (42.9) .76 (.45-1.27) .29 .69 (.38-1.24) .22
Day 90 119 126
Death (%) 245 42 (17.1) 19 (16.0) 23 (18.3) .85 (.44-1.66) .64 .82 (.37-1.82) .72
mRS score (/6) 245 3.5 (1.7) 3.5 (1.7) 3.5 (1.6) 1.0 (.7-1.6) .94 1.0 (.7-1.6) .86
BI 245 57.4 (39.8) 57.1 (39.8) 57.6 (40.0) −.6 (−10.6-9.5) .91 −3.2 (−11.7-5.3) .45
t-MMSE 141 9.1 (7.43) 9.0 (7.4) 9.2 (7.5) −.2 (−2.7-2.3) .89 −1.1 (−3.2-.9) .28
TICS-M 130 18.9 (15.9) 19.2 (15.9) 18.6 (15.9) .7 (−4.9-6.2) .82 −1.4 (−6.1-3.3) .55
Animal naming (/infinity) 136 7.2 (7.5) 7.2 (7.3) 7.2 (7.7) −.6 (−3.1-1.9) .64 −.6 (−3.3-2.1) .66
ZDS (/100) 197 64.3 (24.0) 64.1 (23.4) 64.4 (24.7) −.3 (−7.1-6.4) .92 1.7 (−4.2-7.7) .57
EQ-5D/HUS (/1) 244 .42 (.31) .40 (.30) .43 (.33) −.03 (−.11-.05) .52 −.04 (−.11-.03) .24
EQ-VAS (/100) 213 50.1 (31.5) 50.9 (31.0) 49.4 (32.1) 1.6 (−7.0-10.1) .72 −1.9 (−9.6-5.9) .64
Abbreviations: BI, Barthel Index; EQ-5D, European Quality of Life-5 Dimensions; EQ-VAS, European Quality of Life-Visual Analogue Scale; HUS, health utility status; ICH, intracranial hem-
orrhage; MD, mean difference; mRS, modified Rankin Scale; OR, odds ratio; t-MMSE, Modified telephone Mini-Mental State Examination; SBP, systolic blood pressure; SSS, Scandinavian Stroke
Scale; TICS-M, Modified Telephone Interview for Cognitive Status; t-MMSE, telephone Mini-Mental State Examination; VAS, Visual Analogue Scale; ZDS, Zung Depression Scale.
Data are the number of patients (%), median (interquartile range), or mean (standard deviation). Comparison by logistic regression, ordinal regression, or multiple regression, shown as OR or
MD, with adjustment for age, sex, premorbid mRS score, history of previous stroke, history of diabetes, stroke severity, stroke syndrome (total anterior circulation), SBP, feeding status, time to
randomization, and treatment assignment (glyceryl trinitrate versus none).
Range of scores: SSS: −1 (death) to 0 (coma with quadriplegia) to 58 (normal neurological status); BI: −5 (death) to 0 (severe disability) to 100 (no disability); modified t-MMSE: −1 (death),
0 (severe dementia) to 18 (normal); TICS-M: −1 (death), 0 (severe dementia) to 37 (normal); verbal fluency (number of animals named in 1 minute): −1 (death), 0 (none named) to infinity; HUS
(derived from EQ-5D): −.5 (very poor quality of life), 0 (death) to 1.0 (perfect quality of life); EQ-VAS: −1 (death), 0 (very poor) to 100 (excellent). ZDS: 0 (normal), 100 (severe depression) to
102.5 (death).
The numbers highighted in bold indicate that these values were statistically significant.
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aspects including time window for recruitment, exclu-
sion or inclusion of dysphagia (and so differences in
baseline severity), baseline BP level, length of treat-
ment, and timing of measurement of the primary end
point. In an individual patient data meta-analysis of
COSSACS and ENOS combined, no difference in mRS
score was seen in 284 patients with ICH who were ran-
domized to continue versus to stop taking prestroke
antihypertensive therapy (Woodhouse et al, unpub-
lished). In that meta-analysis, mRS score was worse in
patients randomized to continue treatment, irrespective
of stroke type, if enrolled within 12 hours of onset. This
finding was present in ENOS (unpublished data) but is
not replicated in the present substudy, presumably due
to the small number of patients and wide confidence in-
tervals. BP lowering might reduce death or major disability
if treatment is started within 6 hours of stroke.37-39 However,
the present analysis assessed the issue of continuing or
stopping pre-existing antihypertensive treatment (where
differences in BP level between the treatment groups take
days to develop), whereas the other trials initiated an-
tihypertensive treatment in the hyperacute phase of stroke.
Because it took several days for BP to differ between the
randomized groups, it appears that short-term high BP
level, as occurred in the group that were randomized to
stop treatment temporarily, is not detrimental provid-
ing the difference occurs after the hyperacute period.
Importantly, this observation appears to apply to those
recruited within 12 hours where the BP level was higher
by 28/16 mmHg at 1 week in those stopping treatment
temporarily, a BP difference that was not associated with
a worse outcome.
The strengths of the present study are 2-fold. First, it
assessed a broad population of patients with ICH, with
international enrollment from multiple race–ethnicity
groups, and included patients with a wide range of se-
verity, including those with dysphagia. Second, the data
come from a high-fidelity trial with blinded assessment
of outcomes, independent and masked adjudication of
events, and near-complete follow-up.16 However, 2 limi-
tations should be noted. First, ENOS excluded patients
with very high BP and reduced consciousness (GCS < 8)
or without motor signs. As a result, patients with large
hemorrhages may have been under-represented. Second,
fewer than 5% of patients had bleeding into the poste-
rior fossa and therefore the results cannot be extrapolated
to a population with posterior fossa hemorrhages. Recent
observational data have shown that the BP rise is steeper,
and final levels higher, in such patients as compared with
lobar hemorrhages.3
In conclusion, this subgroup analysis of ENOS was
neutral and did not identify any beneficial effects in con-
tinuing prestroke antihypertensive drugs in patients during
the first week after acute ICH. Although BP lowering
reduces chronic stroke recurrence, the present results
suggest it is reasonable to withhold antihypertensive drugs
taken before the onset of ICH until patients are neuro-
logically stable and appropriate enteral or oral access has
been established.
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